Drugs / Oteseconazole
Oteseconazole
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VIVJOA | — | 2022-04-26 | fda.gov ↗ |
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT02267356 | Feb 2015 → Oct 2016 | tinea unguium | Viamet | Completed | No outcome recorded |
| Phase 2 | NCT02267382 | Feb 2015 → Nov 2016 | vulvovaginal candidiasis | Viamet | Completed | No outcome recorded |
| Phase 2 | NCT01891305 | Aug 2013 → Dec 2014 | tinea pedis | Viamet | Completed | No outcome recorded |
| Phase 2 | NCT01891331 | Aug 2013 → Dec 2014 | vulvovaginal candidiasis | Viamet | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06666322 | May 2025 → Apr 2032 expected | Cryptococcal meningitis, HIV infectious disease | University of Minnesota | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03840616 | Mar 2019 → Dec 2020 | vulvovaginal candidiasis | Mycovia Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03561701 | Aug 2018 → Oct 2020 | vulvovaginal candidiasis | Mycovia Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03562156 | Aug 2018 → Oct 2020 | vulvovaginal candidiasis | Mycovia Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oteseconazole | “VT-1161 (oteseconazole) is an oral agent with increased selectivity for fungal CYP51.” PMID 32818963 ↗ Oct 2021 |
| Known as | Oteseconazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3311228 ↗ |
| Known as | Vivjoa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3311228 ↗ |
| Known as | VIVOJA | “Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis.” PMID 36396498 ↗ Nov 2022 |
| Known as | VT-1161 | “A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)” NCT03561701 ↗6“Oteseconazole (VT-1161) 150mg capsule” NCT03840616 ↗ “Oteseconazole (VT-1161) 150mg capsule” NCT03562156 ↗ |
| Action | Inhibit | “VT-1161 has been designed to inhibit CYP51” NCT01891305 ↗ |
| Modality | Small molecule | — CHEMBL3311228 ↗ |
| Route | Oral | “novel oral agent VT-1161” NCT01891305 ↗ |